Strong balance sheet helps Sun mull larger US acquisition
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries' intent to pursue an acquisition in the US is being led in part by the firm's strong balance sheet and has little to do with unresolved GMP concerns that may be eroding value at its US arm, Caraco.